Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Prostate Cancer
Interventions
RADIATION

Stereotactic Ablative Body Radiotherapy as Monotherapy

The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.

RADIATION

Stereotactic Ablative Body Radiotherapy as a Boost

The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.

Trial Locations (3)

90806

Long Beach Memorial Medical Center, Long Beach

92653

Saddleback Memorial Medical Center, Laguna Hills

92708

Orange Coast Memorial Medical Center, Fountain Valley

All Listed Sponsors
lead

MemorialCare Health System

OTHER